Breaking News Instant updates and real-time market news.

WWD

Woodward

$77.18

-0.5 (-0.64%)

16:09
01/28/19
01/28
16:09
01/28/19
16:09

Woodward backs previously stated outlook for FY19

  • 28

    Jan

  • 30

    Jan

WWD Woodward
$77.18

-0.5 (-0.64%)

12/11/18
BRRR
12/11/18
NO CHANGE
Target $90
BRRR
Outperform
Woodward price target lowered to $90 from $98 at Barrington
Barrington analyst Chris Howe lowered his price target for Woodward to $90 citing the reduction in peer group multiples due to market weakness. The analyst, however, reiterates an Outperform rating on the shares after last week's investor day. From 2019 to 2023, the company expects to achieve annual revenue growth of approximately 8%, Aerospace and Industrial margins of 20%-plus and 16%-plus, respectively, and "superior" cash generation of approximately $2B, Howe tells investors in a research note.
11/20/18
RHCO
11/20/18
UPGRADE
Target $96
RHCO
Buy
Woodward upgraded to Buy at SunTrust on more stable margin view
As reported earlier, SunTrust analyst Michael Ciarmoli upgraded Woodward to Buy from Hold and raised his price target to $96 from $89. The analyst cites his increased confidence around the sustainability of the aerospace operating margins after the company's management produced 570bps in margin expansion over the past 6 years through "flawless execution". Ciarmoli adds that Woodward's legacy industrial revenues have bottomed while noting that its 15.9-times forward earnings valuation is "compelling" as it has declined from 24-times nearly a year ago and also stands below its five-year average.
11/20/18
RHCO
11/20/18
UPGRADE
RHCO
Buy
Woodward upgraded to Buy from Hold at SunTrust
11/09/18
11/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Brookfield (BAM) upgraded to Outperform from Neutral at Credit Suisse with analyst Andrew Kuske saying he believes Brookfield is positioned for a breakout fund raising cycle and doesn't believe the current valuation is reflective of the potential acceleration of growth. 2. Monster Beverage (MNST) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Judy Hong saying concerns over the dispute with Coca-Cola (KO) are overdone and recommends buying shares on weakness. 3. Woodward (WWD) upgraded to Outperform from Market Perform at Barrington with analyst Chris Howe citing the "strong performance" of L'Orange, continued content wins in Aerospace and less volatility in the overall Industrial segment for the upgrade after the company's Q4 results topped expectations. 4. Axon (AAXN) upgraded to Outperform from Neutral at Baird with analyst William Power saying he believes the weakness following its Q3 results are overdone and he believes the new product introductions of Taser 7, Body Camera 3, and a growing software portfolio all provide potential catalysts in 2019. 5. Cree (CREE) upgraded to Buy from Neutral at Goldman Sachs with analyst Brian Lee saying his more in-depth field work and market analysis around the company's silicon carbide opportunity has made him "incrementally more bullish" on its growth potential. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

PFE

Pfizer

$36.34

-0.17 (-0.47%)

07:10
10/17/19
10/17
07:10
10/17/19
07:10
Initiation
Pfizer initiated  »

Pfizer reinstated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

GILD

Gilead

$65.36

0.02 (0.03%)

07:08
10/17/19
10/17
07:08
10/17/19
07:08
Initiation
Gilead initiated  »

Gilead reinstated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

MAIN

Main Street

$42.08

0.155 (0.37%)

07:08
10/17/19
10/17
07:08
10/17/19
07:08
Earnings
Main Street declares semi-annual supplemental cash dividend of 24c in December »

Main Street declared its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

POOL

Pool Corp.

$200.56

-4.63 (-2.26%)

07:08
10/17/19
10/17
07:08
10/17/19
07:08
Earnings
Pool Corp. raises FY19 EPS view $6.20-$6.40 from $6.09-$6.34 

Consensus $6.22.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 13

    Nov

PM

Philip Morris

$79.12

0.8 (1.02%)

07:08
10/17/19
10/17
07:08
10/17/19
07:08
Hot Stocks
Philip Morris revises FY19 shipment volume assumption to "down 1% - down 1.5" »

Prior guidance was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

BIIB

Biogen

$227.79

1.75 (0.77%)

07:07
10/17/19
10/17
07:07
10/17/19
07:07
Initiation
Biogen initiated  »

Biogen reinstated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AZN

AstraZeneca

$43.80

-0.41 (-0.93%)

07:07
10/17/19
10/17
07:07
10/17/19
07:07
Hot Stocks
AstraZeneca says trastuzumab deruxtecan granted FDA Priority Review »

AstraZeneca and Daiichi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

POOL

Pool Corp.

$200.56

-4.63 (-2.26%)

07:07
10/17/19
10/17
07:07
10/17/19
07:07
Earnings
Pool Corp. reports Q3 EPS ex-items $1.84, consensus $1.78 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 13

    Nov

TXMD

TherapeuticsMD

$3.70

-0.22 (-5.61%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Initiation
TherapeuticsMD initiated  »

TherapeuticsMD initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$79.12

0.8 (1.02%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Earnings
Philip Morris lowers FY19 EPS view to 'at least $4.73' from 'at least $4.94' »

Consensus $5.21. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NFLX

Netflix

$286.83

2.59 (0.91%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Recommendations
Netflix analyst commentary  »

KeyBanc lowers estimates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

NBRV

Nabriva Therapeutics

$2.01

0.08 (4.15%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Conference/Events
Nabriva Therapeutics management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

BBIO

BridgeBio

$17.92

-0.6 (-3.24%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Hot Stocks
BridgeBio reports preclinical data on infigratinib in treating achondroplasia »

BridgeBio Pharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$203.28

-1.37 (-0.67%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Initiation
Amgen initiated  »

Amgen reinstated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

UCBJY

UCB

$0.00

(0.00%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Hot Stocks
UCB says bimekizumab Phase 3 psoriasis study meets all endpoints »

UCB announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SASR

Sandy Spring Bancorp

$33.42

0.21 (0.63%)

07:04
10/17/19
10/17
07:04
10/17/19
07:04
Earnings
Sandy Spring Bancorp reports Q3 EPS 82c, consensus 80c »

"In the third…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

AUG

Auryn Resources

$1.28

0.09 (7.56%)

07:02
10/17/19
10/17
07:02
10/17/19
07:02
Hot Stocks
Auryn Resources stakes additional claims at Sombrero North project area »

Auryn Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$45.53

0.33 (0.73%)

, WBA

Walgreens Boots Alliance

$54.66

0.15 (0.28%)

07:02
10/17/19
10/17
07:02
10/17/19
07:02
Hot Stocks
Centene, Walgreens Boots Alliance, RxAdvance announce partnership »

Centene (CNC), Walgreens…

CNC

Centene

$45.53

0.33 (0.73%)

WBA

Walgreens Boots Alliance

$54.66

0.15 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

MIST

Milestone Pharmaceuticals

$18.75

0.25 (1.35%)

07:02
10/17/19
10/17
07:02
10/17/19
07:02
Conference/Events
Milestone Pharmaceuticals management to meet with Piper Jaffray »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

PM

Philip Morris

$79.12

0.8 (1.02%)

07:02
10/17/19
10/17
07:02
10/17/19
07:02
Earnings
Philip Morris reports Q3 adjusted EPS $1.43, consensus $1.36 »

Reports Q3 net revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

MDGL

Madrigal Pharmaceuticals

$86.78

-0.49 (-0.56%)

07:00
10/17/19
10/17
07:00
10/17/19
07:00
Conference/Events
Madrigal Pharmaceuticals management to meet with Oppenheimer »

Luncheon Meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

ALXN

Alexion

$99.41

-5.435 (-5.18%)

06:58
10/17/19
10/17
06:58
10/17/19
06:58
Initiation
Alexion initiated  »

Alexion reinstated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

PPG

PPG

$118.89

0.665 (0.56%)

06:58
10/17/19
10/17
06:58
10/17/19
06:58
Hot Stocks
PPG CEO says 'we made excellent progress executing on our key initiatives' »

"We delivered strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

MNST

Monster Beverage

$56.54

0.27 (0.48%)

06:57
10/17/19
10/17
06:57
10/17/19
06:57
Downgrade
Monster Beverage rating change  »

Monster Beverage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULC

Fulcrum Therapeutics

$4.71

-0.15 (-3.09%)

06:57
10/17/19
10/17
06:57
10/17/19
06:57
Conference/Events
Fulcrum Therapeutics management to meet with SVB Leerink »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.